Delayed embolization of an Amplatz® canine duct occluder in a dog

A 5-year old, 5.8 kg, castrated male Pomeranian was diagnosed with a type IIa patent ductus arteriosus (PDA) with a minimal ductal diameter of 3.5 mm and ampulla width of 7.1 mm based on angiographic assessment. A 6 mm Amplatz^® Canine Duct Occluder (ACDO) was deployed within the PDA. Once deployed, the device assumed it's native shape and back-and-forth maneuvering was performed with the delivery cable to assess device stability. Device position and complete occlusion were confirmed with both angiography and transesophageal echocardiography prior to and after release of the device. The device location was confirmed within the ductus arteriosus by echocardiography prior to discharge. The dog was discharged with instructions for strict activity restriction. Two days after discharge, the dog was left unsupervised in the backyard and shortly afterwards was found coughing with severe respiratory distress. The dog was evaluated at an emergency hospital and thoracic radiographs documented embolization of the ACDO to the main pulmonary artery along with a severe alveolar pattern throughout the right lung fields. Shortly after obtaining thoracic radiographs, the dog experienced cardiopulmonary arrest with unsuccessful resuscitation. This case describes a possible complication of transcatheter PDA occlusion with an ACDO, which has not been previously reported. An incident report, or catalog of adverse events with these devices, may prove useful in identifying additional fatal complications that others may have encountered, but are not reported in the literature. The report of this complication emphasizes the importance of strict activity restriction after device placement in dogs.     

ANXITANE® tablets reduce fear of human beings in a laboratory model of anxiety-related behavior

Anxiety and fear are common underlying factors in many canine behavior problems that impair the human–pet bond and often result in abandonment, relinquishment, or euthanasia. A combination of behavioral and pharmacological interventions is used to ameliorate the behavioral signs associated with anxiety-related behaviors in dogs, but there continues to be need for effective interventions. The current study examined the effects of the nutraceutical ANXITANE^® (l-Theanine) chewable tablets on fear of unfamiliar human beings. We first characterized dogs as anxious on the basis of the existence of a fear response to human beings in their home-pen. We then demonstrated that dogs characterized as anxious (N = 10) showed reduced interaction with an unknown human being as compared with normal controls (N = 7). The effect of an administration of ANXITANE^® tablets (N = 5) on these anxious Beagle dogs was compared with placebo (N = 5). Objective behavioral measures of anxiety were obtained using an open-field test, a human interaction test, and an actiwatch protocol that allowed monitoring of activity over 24-hours. The ANXITANE^® tablets-treated dogs showed greater human interaction and approach than the placebo control group, and no side effects related to treatment, including motor stimulant or sedative effects, were seen. The current study suggests that ANXITANE^® tablets are effective for reducing fearful behavior toward unfamiliar human beings in dogs and supports their use for treating anxiety-related behaviors.     

Effect of Tomanol® on the pharmacokinetics and tissue distribution of penicillin G in dairy cows

Summary

Following concomitant intravenous administration of Tomanol® and sodium penicillin G to six Dutch Friesian dairy cows a significant decrease in total body clearance of penicillin (34.7%) and a prolongation of the elimination half‐life of penicillin (17.2%) was observed. Tomanol® did not affect other pharmacokinetic parameters such as rate constants of drug transfer (k₁₂/k₂₁, α en β), distribution volume of the central compartment (V₁), and extrapolated serum drug levels. Intravenous or intramuscular administration of Tomanol® had no effect on the tissue distribution of penicillin G, because neither a change in the ratios of muscle to serum and of kidney cortex to serum nor a change in an induced steady state level of low penicilline G serum concentrations was observed. From the data obtained it is concluded that concomitant Tomanol® administration with penicillin induces an elevation of the serum penicillin concentration and prolongs the persistence of penicillin residues in carcass meat and organs.     

Genome-wide scan for runs of homozygosity in the composite Montana Tropical® beef cattle

The aim of this study was to assess the distribution of runs of homozygosity (ROH) and autozygosity islands in the composite Montana Tropical^® beef cattle to explore hotspot regions which could better characterize the different biological types within the composite breed. Montana animals (n = 1,436) were genotyped with the GGP-LD BeadChip (~30,000 markers). ROH was identified in every individual using the plink v1.90 software. Medium and long ROH prevailed in the genome, which accounted for approximately 74% of all ROH detected. On an average, 2.0% of the genome was within ROH, agreeing with the pedigree-based inbreeding coefficient. The Montana cattle with a higher proportion of productive breed types showed the highest number of autozygosity islands (n = 17), followed by those with a higher proportion of breeds adapted to tropical environments (n = 15). Enriched terms (p < .05) associated with the immune and inflammatory response, homeostasis, reproduction, mineral absorption, and lipid metabolism were described within the autozygosity islands. In this regard, over-represented GO terms and KEGG pathways described in this population may play a key role in providing information to explore the genetic and biological mechanisms together with the genomic regions underlying each biological type that favoured their optimal performance ability in tropical and subtropical regions.     

Review of the measuring precision of the new Meibometer® MB550 through repeated measurements in dogs

Objective A meibometer is a device to measure the delivery rate of lipids on the eyelid margin. The aim of this study is to determine the measuring precision of the new Meibometer^® MB550 (Courage-Khazaka electronic GmbH, 50829, Cologne, Germany), linked to a computer, by means of repeated measurements in dogs by different examiners. Procedure Two investigators measured the lipid rate on the eyelid margin in 10 healthy dogs for 10 days. One examiner measured the right eye (OD) and the other measured the left eye (OS) for 5 days. After 5 days, the eyes to be measured were switched between the examiners. The new device was able to record all measurement values as charts and curves in comparison to the previous Meibometer, which displayed only one value. Results Mean meibomium lipid level ± SD in the OD and OS of 10 dogs in 10 days was 211 ± 48 MU and 205 ± 41 MU (meibometer units), respectively. There was no significant difference between OD and OS, but a broad distribution of the values could be found. Gender did not influence the measurements. A significant difference was determined between the measurements in the first 5 days to those in the following 5 days. There was, therefore, also a significant difference in the measurements of the 2 examiners. Conclusion Meibometry is a minimally invasive lipid measuring method on the eyelid margin. Repeated measurement results obtained by two examiners, with the new device Meibometer MB550 linked to a computer, showed a wide range of values. The measuring precision of the new Meibometer MB550 is therefore questionable.     

Immune response during the onset of coliform mastitis in dairy cows vaccinated with STARTVAC®

The immune response during the onset of coliform mastitis in vaccinated cows was investigated by measuring lactoferrin (LF), interleukin-8 ( IL-8), and interleukin-1β (IL-1β) concentrations and somatic cell counts in 28 milk samples at the onset of acute coliform mastitis (ACM) and 73 milk samples at the onset of peracute coliform mastitis (PCM). Vaccinated ACM, unvaccinated ACM, and vaccinated PCM showed significantly higher values for LF and IL-1β levels than unvaccinated PCM (p < .01). The IL-8 concentration was lower in vaccinated PCM than in unvaccinated PCM (p < .05). There was no significant difference in somatic cell counts for each parameter. There were no significant differences in the parameters between vaccinated and unvaccinated ACM cows, or vaccinated ACM and PCM cows. From the above results, it is suggested that mastitis vaccination improved the early immune response, particularly at the onset of PCM, and played a large role in host defense against the initial infection.     

The advantages of using a combination of LDL and glutamine in comparison with TRIS egg yolk and Equex® STAMP extenders in the cryopreservation of canine semen

Twenty semen samples taken from 5 dogs were frozen in liquid nitrogen at ?196 °C in four different extenders: one control extender based on 20% egg yolk, 6% LDL alone (low density lipoproteins: the active cryoprotective principle in chicken egg yolk), 6% LDL combined with 20 mmol glutamine, and Equex® (a reference extender that we wish to compare with the LDL-glutamine combination). After thawing, spermatozoal motility was evaluated using a HAMILTON THORNE CERROS 12 image analyzer; the percentage of motile spermatozoa was 27.7% in the egg yolk extender (p < 0.05), 49.9% with 6% LDL alone (p > 0.05), 54.7% in the 6% LDL + 20 mmol glutamine extender, and 47.9% with Equex® (p > 0.05). The motility parameters (VAP, VCL, VSL and ALH) were also superior in the 6% LDL + 20 mmol glutamine extender in comparison with the other extenders.Finally, the spermatozoa were generally better protected during freezing with the 6% LDL + 20 mmol glutamine association than with the egg yolk, 6% LDL, or Equex extenders in terms of the flagellar plasma membrane (HOS test), DNA (Acridine orange test), and acrosome integrity (Spermac® test: no significant difference). The Equex® extender obtained the best results for the acrosome, followed by 6% LDL + 20 mmol glutamine (FITC-PSA test: p < 0.05 between each extender).     

A pilot study of 4CYTE™ Epiitalis® Forte,a novel nutraceutical,in the management of naturally occurring osteoarthritis in dogs

The primary goal of this pilot study was to assess, the efficacy of a new nutraceutical, 4CYTE™ Epiitalis® Forte, containing, as a standalone, a proprietary plant oil extract, Epiitalis, in dogs presenting with signs of osteoarthritis (OA). Fifty dogs aged 9.2 (±3.2) years with signs of naturally occurring OA were included in this report. They were free of other comorbidities and were not on any medications except for those utilised for managing their OA. In these dogs, the current treatments were continued to avoid any sudden changes in their disease management. The effects of the 4CYTE Epiitalis Forte were assessed both at the beginning and at the end of a 1 month-long treatment period. The evaluation consisted of an objective lameness assessment (TPI%[total pressure index]) using a gait analysis (GAITRite® Portable Walkway System) and a subjective quality-of-life questionnaire, the Helsinki Chronic Pain Index (HCPI). Additional exploratory objective measurements included the Symmetry Index (SI) and the fore/hind limb ratio (T/P TPI%). Of dogs, 74% (34/46) registered a numerical improvement in TPI% in their worse limb. In addition, of the 93.5% of the dogs that demonstrated improvement in their HCPI scores by at least 5% on the quality-of-life questionnaire, 79% demonstrated improvements in gait based on TPI%. Finally, there were improvements measured in both exploratory objective endpoints SI and T/P TPI%. These encouraging results will be used to develop a protocol for a follow-up placebo-controlled randomised study to confirm the efficacy of this new nutraceutical for dogs suffering from OA.     

Evaluation of Precision Xceed® meter for on-site monitoring of blood β-hydroxybutyric acid and glucose concentrations in dairy sheep

The accuracy of the Precision Xceed® hand-held meter as an on-site method for measuring blood β-hydroxybutyric acid (BHBA) and glucose concentrations, for the diagnosis of pregnancy toxemia and ketosis in dry and lactating dairy sheep, was assessed. Five to eight hours after the start of the morning feed, blood was collected once from 193 clinically healthy sheep (143 dry and 50 lactating). BHBA and glucose analyses were performed with serum in the laboratory, and with whole blood with the Precision Xceed®. Overall, BHBA and glucose determinations by the two methods were not statistically different (P > 0.05). Strongly significant positive correlations were found for glucose and BHBA concentrations between the Precision Xceed® and laboratory results (r = 0.76, n = 150, P < 0.01 and r = 0.99, n = 193, P < 0.01, respectively). The Precision Xceed® was highly sensitive (98.6%) and specific (98.2%), and had excellent test agreement for the detection of pregnancy toxemia and ketosis.     

Effect of TEX-OE® treatment on the development of heat shock proteins in commercial broiler chicks and the impact on performance indicators in the grow-out period

1. Heat shock proteins (HSPs) are highly conserved proteins, shown to protect organisms against physical and physiological stress.

2. TEX-OE^® is a patented total extract of the fruit of Opuntia ficus indica, which has been demonstrated to accelerate the development of HSPs in several animal species.

3. One-day-old commercial broiler chicks were treated with TEX-OE^®; HSP was measured by enzyme-linked immunosorbent assay (ELISA), and a large commercial field trial investigated key performance indicators (KPIs) in treated versus untreated controls chicks.

4. TEX-OE^® significantly increased HSP concentrations in treated chicks versus controls. Final cumulative mortality, liveweight and percentage factory-rejects were better than in controls.

5. The accelerated HSP response may enable chicks to cope with early stressors, which is reflected in improved KPIs.     

Case Study: Synchronization of Estrus and Fertility in Gilts Administered P.G. 600® After Treatment with Regu-mate® for 14 or 18 Days

The objective was to determine the effects of duration of progestin exposure prior to gonadotropin treatment on the synchronization of estrus and fertility in gilts. Gilts were fed daily a complete diet containing 15 mg Regu-mate® (Intervet America Inc., Millsboro, DE) for 14 (n = 19) or 18 (n = 18) d. Twenty-four hours after the last feeding of Regu-mate®, all gilts received an i.m. injection of P.G. 600® [400IU pregnant mare serum gonadotropin (PMSG) and 200 IU human chorionic gonadotropin (hCG); Intervet America Inc.]. Gilts were bred artificially 12 and 24 h after first detection of standing estrus. More 18-d (33.3%) than 14-d treated gilts (5.3%) were in estrus on the peak day (d 4.0) after P.G. 600® injection (P=0.02). The percentage of gilts displaying estrus < 7 d after P. G. 600® injection was greater (P=0.06) for the 18-d treatment (88.9%) than for the 14-d treatment (63.2%). Farrowing rate tended to be greater (P=0.17) for gilts exposed to Regu-mate® for 18 d (75%) compared with 14 d (50%). Total pigs born (P=0.43), pigs born live (P=0.63), stillborns (P=0.62), and total litter weight (P=0.52) were similar between groups. The number of mummified fetuses tended to be higher (P=0.11) for gilts in the 18-d treatment group (0.8 ± 0.2) compared with the 14-d treatment group (0.2 ± 0.3). In summary, the precision of estrus synchronization and reproduction was greater in gilts given P.G. 600® after 18 d compared with 14-d Regu-mate® treatment.     

Effects of AGRADO® on Growth Performance and Health of Newly Received Feedlot Calves

Two experiments were conducted to determine the effect of an antioxidant (AGRADO®; Solutia Inc., St. Louis, MO) on the growth, gain to feed ratio, and health of receiving calves. In Experiment 1, 96 mixed breed heifer calves (206 ± 1.4 kg initial BW) were purchased at sale barns and delivered as a single group to the research facility near Fayetteville. All heifers were fed a total mixed diet containing 30% cottonseed hulls, 53% cracked corn, and 11% soybean meal for 42 d with either 0 or 150 mg AGRADO®/kg diet. Fewer (P<0.05) of the heifers fed supplemental AGRADO® were treated for respiratory disease (73% vs 83%), and medication cost was lower (P<0.05) for heifers fed supplemental AGRADO ($6.33 vs $9.49 per pen). Supplemental AGRADO® did not affect (P>0.10) ADG, daily feed intake, and gain to feed ratio. In Experiment 2, 86 bull and steer calves (237 ± 2.2 kg initial BW) were managed and fed as in Experiment 1 for a 41-d study. In this trial, supplemental AGRADO® had no significant effect on the number of sick calves or medication costs, but gain to feed ratio was improved (P<0.05) during the first 28 d of the trial. These results indicate that supplemental AGRADO® may improve the health or growth performance of newly received feedlot cattle.